drugset / Trial / NCT00392197

Study of Aripiprazole in Patients With Schizophrenia- Effects on Glucose Metabolism-

NCT00392197

Phase 4 Completed 111 enrolled Otsuka Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to examine the effects of aripiprazole on glucose metabolism in schizophrenic patients without hyperglycemia and diabetes mellitus or any history thereof.

Timeline

Start
2006-11
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 6 mg Oral
Subject Aripiprazole Other / unclassified 24 mg Oral

Indications